IMDX Company Profile and Key Details
NASDAQ : IMDX
Insight Molecular Diagnostics
$3.75
0.17+4.75%
At Close 4:00 PMPrice Chart
Stock Price Today
Insight Molecular Diagnostics Inc. (IMDX) stock declined over -6.13%, trading at $3.52 on NASDAQ, down from the previous close of $3.75. The stock opened at $3.69, fluctuating between $3.32 and $3.70 in the recent session.
Stock Snapshot
3.75
Prev. Close
94.48M
Market Cap
3.32
Day Low
-2.13
P/E Ratio
-1.65
EPS (TTM)
N/A
Cash Flow per Share
3.69
Open
26.84M
Number of Shares
3.695
Day High
27.18%
Free Float in %
N/A
Book Value
534.73K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 22, 2026 | 3.65 | 4.10 | 3.58 | 3.75 | 543.43K |
| Apr 21, 2026 | 4.30 | 4.55 | 3.55 | 3.58 | 464.82K |
| Apr 20, 2026 | 3.80 | 4.02 | 3.75 | 3.99 | 200K |
| Apr 17, 2026 | 3.58 | 3.87 | 3.41 | 3.84 | 265.27K |
| Apr 16, 2026 | 3.39 | 3.64 | 3.13 | 3.51 | 468.39K |
| Apr 14, 2026 | 3.05 | 4.07 | 3.03 | 3.61 | 834.76K |
| Apr 13, 2026 | 3.18 | 3.18 | 2.70 | 3.00 | 235.63K |
| Apr 10, 2026 | 3.21 | 3.22 | 2.66 | 3.17 | 406.44K |
| Apr 09, 2026 | 3.00 | 3.38 | 2.86 | 3.18 | 535.16K |
| Apr 08, 2026 | 3.36 | 3.61 | 2.96 | 3.02 | 280.92K |
| Apr 07, 2026 | 3.34 | 3.35 | 2.99 | 3.21 | 235.19K |
| Apr 06, 2026 | 3.71 | 3.72 | 3.12 | 3.37 | 192.24K |
| Apr 02, 2026 | 3.40 | 3.79 | 3.26 | 3.76 | 292.76K |
| Apr 01, 2026 | 3.03 | 3.45 | 2.88 | 3.44 | 273.85K |
| Mar 31, 2026 | 2.50 | 3.60 | 2.42 | 3.28 | 1.19M |
| Mar 30, 2026 | 3.48 | 3.66 | 2.42 | 2.55 | 442.21K |
| Mar 27, 2026 | 4.17 | 4.37 | 3.29 | 3.56 | 341K |
| Mar 25, 2026 | 4.12 | 4.45 | 3.69 | 4.14 | 159.45K |
| Mar 24, 2026 | 4.00 | 4.11 | 3.44 | 4.00 | 318.5K |
| Mar 23, 2026 | 4.26 | 4.47 | 3.98 | 4.00 | 115.61K |
Contact Details
About Company
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Company Information
| Employees | 46 |
| Beta | 1.35 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-12.16-1.51%
argenx SE$793.22REGN-0.78-0.10%
Regeneron Pharmaceuticals, Inc.$746.58UTHR0.83+0.14%
United Therapeutics Corporation$574.29MDGL1.45+0.27%
Madrigal Pharmaceuticals, Inc.$529.14VRTX1.08+0.25%
Vertex Pharmaceuticals Incorporated$437.67PRAX-3.55-1.04%
Praxis Precision Medicines, Inc.$337.29KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY2.15+0.70%
Alnylam Pharmaceuticals, Inc.$310.58KRYS3.28+1.20%
Krystal Biotech, Inc.$275.94ASND-9.24-3.85%
Ascendis Pharma A/S$231.05Technical Performance
Short-term trend indicators are mixed aligned (SMA20 -7.92%, SMA50 -10.86%, SMA200 26.77%). The stock’s 14-day RSI is 42.11 (neutral), while the ATR of 0.51 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.37% below its high and over 143.35% above its low. Average 10-day trading volume of 430.33 thousand shares is significantly above the 3-month average of 187.65 thousand, indicating heightened recent market interest.
Dividend & Fair Value
Dividend and splits history remains an important factor for investors monitoring long-term returns.
Earnings & Analyst Outlook
Insight Molecular Diagnostics Inc. generated EPS of -$2.83 over the past year. Five-year average earnings growth is 11.82%. Wall Street analysts project EPS growth of 49.38% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $4.25. The high target offers 220.0% upside. The low target suggests 13.33% downside. The mean target is $8.42. This offers 124.53% upside. Insight Molecular Diagnostics Inc. earnings surprise history is a mixed track record. The quarter that ended November 11, 2025, missed forecasts by -16.65%. The prior quarter beat by 47.83%. Over the last six quarters, Apple has recorded several small beats. These include 122.73% in November 12, 2024.
Shareholding & Insider Activity
Insight Molecular Diagnostics Inc. has 28.62 million shares outstanding. The public float is 7.78 million shares, elevated short interest at 2.05% of float. This equals 277.27 thousand shares. The short ratio is 5.46 days. Institutional investors hold 68.2% of the float. Insiders own 20.09%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.
Financial & Profitability Overview
On valuation metrics, Insight Molecular Diagnostics trades at a P/E of -2.11, P/S of 23.00 and P/B of -3.37. The current ratio is 1.27 and quick ratio is 1.23. Operationally, the company’s inventory turnover is 8.67 and cash conversion cycle is -96.60 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.11, supported by a cash flow-to-debt ratio of -6.34.
Frequently Asked Questions
What is the current Insight Molecular Diagnostics Inc. (IMDX) stock price?
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) stock price is $3.52 in the last trading session. During the trading session, IMDX stock reached the peak price of $3.70 while $3.32 was the lowest point it dropped to. The percentage change in IMDX stock occurred in the recent session was -6.13% while the dollar amount for the price change in IMDX stock was - $0.23.
IMDX's industry and sector of operation?
The NASDAQ listed IMDX is part of Biotechnology industry that operates in the broader Healthcare sector. Insight Molecular Diagnostics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of IMDX?
No Data
How IMDX did perform over past 52-week?
IMDX's closing price is 60.94% higher than its 52-week low of $2.33 where as its distance from 52-week high of $8.51 is -55.93%.
How many employees does IMDX have?
Number of IMDX employees currently stands at 46.
Link for IMDX official website?
Official Website of IMDX is: https://imdxinc.com
How do I contact IMDX?
IMDX could be contacted at phone 949 409 7600 and can also be accessed through its website. IMDX operates from 15 Cushing, Nashville, TN 92618, United States.
How many shares of IMDX are traded daily?
IMDX stock volume for the day was 534.73K shares. The average number of IMDX shares traded daily for last 3 months was 196.81K.
What is the market cap of IMDX currently?
The market value of IMDX currently stands at $94.48M with its latest stock price at $3.52 and 26.84M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep